Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

8 evidence topics · 19 sources

Summary
  • No currently available therapy for NPC is curative. Before the LEMBAZ approval, two therapies were approved for NPC, and neither had been shown to reduce the risk of death.
  • Age and weight limits: FDA-approved treatments for the neurological manifestations of NPC are indicated only for patients 2 years of age or older (arimoclomol, in combination with miglustat) or weighing 15 kg or more (levacetylleucine), leaving limited options for early infantile-onset NPC. An open-label substudy of arimoclomol in infants younger than 24 months enrolled 5 participants aged 14 to 23 months, and the company anticipates filing a supplemental application for this age group in Q1 2027.
  • Miglustat: miglustat is used off-label for NPC in the United States. In a comparison of 10 treated and 16 untreated individuals with early infantile NP-C, all treated patients developed loss of psychomotor acquisitions or additional neurological symptoms, and the authors report that “Miglustat allowed no significant long-term neurodevelopmental improvement nor significant increase of survival in patients with early infantile NP-C”. In a pooled observational analysis, the hazard ratio for mortality with miglustat was 0.671 in early infantile patients, a result that did not achieve statistical significance, and 0.364 (95% CI 0.165, 0.801) in late infantile patients.
  • Levacetylleucine: the randomized, placebo-controlled crossover trial enrolled 60 participants with a median age of 25 years (range 5 to 67 years) and treated each period for 12 weeks; the estimated treatment difference in the fSARA total score was -0.4 (95% CI -0.7, -0.2).
  • Arimoclomol: efficacy was demonstrated in patients receiving background miglustat, with a placebo-subtracted difference in the rescored 4-domain NPCCSS of -2.2 (95% CI -3.8, -0.6) at month 12. The FDA determined that evidence for arimoclomol monotherapy was insufficient, and after re-examination on 12 November 2026 the European Medicines Agency confirmed its recommendation to refuse marketing authorisation for arimoclomol (Meplyffa).
  • Evidence gaps: the arimoclomol and levacetylleucine trials did not address nonneurological manifestations such as liver disease, no published studies address coadministration of the two drugs, and data beyond 5 years are extremely limited. Differences in study design, outcome measures, and follow-up preclude direct comparison between therapies.
  • Other cyclodextrin products: in the TransportNPC phase 3 trial of intravenous Trappsol Cyclo (remibetadex), the primary endpoint at Week 96 did not achieve statistical significance (p=0.19), and hearing-related adverse events occurred in 15.6% of participants receiving Trappsol Cyclo and 13.3% receiving placebo; an NDA was submitted on October 28, 2026. One analysis concluded that HPβCD remains investigational and that hearing impairment is an important safety concern.
  • Supportive care: most other options are supportive in nature, and for many individuals clinical trial participation may be the only access to disease-modifying treatment.